Skip to content
Clinical Trials – home
Therapeutic area

Vascular disorders – page 3

  • 846 clinical trials
  • 351 recruiting
  • 382 conditions
  • 28 countries

Conditions in this area

382 conditions with trials, the busiest first

Clinical trials in Vascular disorders

846 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

846 clinical trials

A double‑blind, placebo‑controlled trial of oral BI 1015550 in patients with systemic sclerosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:BI 1015550
  • Sponsor:Boehringer Ingelheim Espana S.A.

Safety Study of CD19.CAR T Cells in Patients with Autoimmune‑Associated Severe Interstitial Lung Fibrosis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:T Lymphocytes Transduced With A Rv-Sfg.cd19.Cd28.4-1Bbzeta Retroviral Vector
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Effect of Lepodisiran on Coronary Plaque in Adults with Elevated Lipoprotein(a) and Established Atherosclerotic Cardiovascular Disease or High Risk for First Event

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Substances:LY3819469 sodium
  • Sponsor:Eli Lilly & Co.

Ticagrelor, Acetylsalicylic Acid and Prasugrel in Patients with Acute Coronary Syndrome: A Study of Antiplatelet Management

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz

Assessing Hemodynamic Effect and Safety of TX000045 in Adults with Pulmonary Hypertension Secondary to Interstitial Lung Disease

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:TX000045

Triple vs dual therapy with rosuvastatin, ezetimibe and bempedoic acid in patients with atherosclerotic heart disease and high cholesterol undergoing revascularisation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bempedoic Acid
  • Sponsor:Medical University Of Graz

Discontinuing Acetylsalicylic Acid vs Continued Use in Patients ≥ 65 Years with Stable Chronic Coronary Syndrome

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Odense University Hospital

Study of Benralizumab Safety, Pharmacokinetics, and Efficacy in Children with Eosinophilic Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Benralizumab
  • Sponsor:AstraZeneca AB

Safety of flecainide acetate compared with amiodarone hydrochloride and sotalol in patients with atrial fibrillation and stable coronary artery disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Flecainide Acetate
  • Sponsor:UZ Leuven

Embolism

Recruiting

Study of REGN7508 versus apixaban for treating and preventing cancer-associated blood clots in adults with solid or blood cancers

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Bempedoic acid in drug combination for patients with coronary artery disease without prior cardiovascular events

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Daiichi Sankyo Europe GmbH

Iodixanol in Cerebral Angiography for Patients with Unruptured Intracranial Aneurysms

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Iodixanol
  • Sponsor:Les Hopitaux Universitaires De Strasbourg

Substances studied in this area

The therapies tested most often in Vascular disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.